Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 9, 2008 - Issue 13
Submit an article Journal homepage
169
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma

Mark A Feitelson Temple University, Department of Biology, College of Science and Technology, Suite 409, BioLife Science Building, 1900 North 12th Street, Philadelphia, PA 19122, USA +1 215 204 8434; +1 215 204 8349; [email protected]; Temple University, Center for Biotechnology, Philadelphia, PA, USA
,
Marcia M Clayton Temple University, Department of Biology, College of Science and Technology, Suite 409, BioLife Science Building, 1900 North 12th Street, Philadelphia, PA 19122, USA +1 215 204 8434; +1 215 204 8349; [email protected]
,
Helena MGPV Reis MIT Portugal Program, Av. Antonio Jose de Almeida, 12 1000-043 Lisboa, Portugal
,
Guoyi Wu Temple University, Department of Biology, College of Science and Technology, Suite 409, BioLife Science Building, 1900 North 12th Street, Philadelphia, PA 19122, USA +1 215 204 8434; +1 215 204 8349; [email protected]
&
Eva Ping Lu Shanghai USINO Biosciences Co. Ltd, Shanghai, China
Pages 2233-2245 | Published online: 19 Aug 2008

Bibliography

  • Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985;317:489-95
  • Feitelson MA. HBV and cancer. Concepts in viral pathogenesis. New York: Springer; 1986. p. 269-75
  • Broelsch CE, Frilling A, Malago M. Hepatoma – resection or transplantation. Surg Clin N Am 2004;84:495-511
  • De Wilt JHW, Van Etten B. Isolated hepatic perfusion: experimental evidence and clinical utility. Surg Clin N Am 2004;84:627-42
  • Elias D, De Baere T, Sideris L, Ducreux M. Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions. Surg Clin N Am 2004;84:607-26
  • Nicholl MB, Bilchik AJ. Thermal ablation of hepatic malignancy: useful but still not optimal. Eur J Surg Oncol 2008;34:318-23
  • Feitelson MA. Hepatocellular injury in hepatitis B and C virus infections. Clin Lab Med 1996;16:307-24
  • Beasley RP, Hwang LY. Epidemiology of hepatocellular carcinoma. In Viral hepatitis and liver disease. New York: Grune and Stratton, Inc.; 1984. p. 209-24
  • Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and HBV. A prospective study of 22,707 men in Taiwan. Lancet 1981;ii:1129-32
  • Asselah T, Lada O, Moucari R, et al. Interferon therapy for chronic hepatitis B Clinics Liver Dis 2007;11:839-49
  • Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care 2007;13:S319-26
  • Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007;14:S82-8
  • Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. Interferon: cellular executioner or white knight? Curr Med Chem 2007;14:1279-89
  • Garcia MA, Gil J, Ventoso I, et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006;70:1032-60
  • Suzuki K, Ohkoshi S, Yano M, et al. Sustained biochemical remission after interferon treatment may closely be related to the end of treatment biochemical response and associated with a lower incidence of hepatocarcinogenesis. Liver Int 2003;23:143-7
  • Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005;25:S40-7
  • Schaefer S. Hepatitis B virus genotypes in Europe. Hepatol Res 2007;37:S20-6
  • Wang Z, Huang Y, Wen S, et al. Hepatitis B virus genotypes and subgenotypes in China Hepatol Res 2007;37:S36-41
  • Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13:211-20
  • Schinazi RF, Hernandez-Santiago B, Hurwitz SJ. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res 2006;71:322-34
  • Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-90
  • Min AD. Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis 2007;11:851-68
  • Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10
  • Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
  • Scotto G, Palumbo E, Fazio V, et al. Prolonged lamivudine treatment in patients with chronic active anti-HBe-positive hepatitis. Am J Ther 2006;13:218-22
  • Alexander G, Baba CS, Chetri K, et al. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol 2005;5:29
  • Natsuizaka M, Hige S, Ono Y, et al. Long term follow up of chronic hepatitis B after the emergence of mutations in the HBV virus polymerase region. J Viral Hepat 2005;12:154-9
  • Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004;11:439-42
  • Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32
  • Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-26
  • Lau GKK, Piratvisuth T, Xian Luo K, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
  • Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
  • Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005;365:123-9
  • Chan HL, Leung NW, Hui AY, et al. A randomized controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon alpha-2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-50
  • Dienstag JL. Looking to the future: new agents for chronic hepatitis B. Am J Gastroenterol 2006;101:S19-25
  • Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
  • Sherman M. Personal view: the management of chronic hepatitis B infection. Aliment Pharmacol Ther 2006;23:857-69
  • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 2003;348:800-7
  • Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxal for HBeAg negative chronic hepatitis B. N Engl J Med 2005;352:2673-81
  • Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
  • Perrillo R, Hann HW, Mortimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90
  • Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27
  • Hadziyannis S, Tassopoulos N, Chang TT, et al. Long term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg negative chronic hepatitis B: results after 5 years of therapy. Hepatology 2005;43:S755
  • Seifer M, Hamatake RK, Colonno RJ, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8
  • Innaimo SF, Seifer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8
  • Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
  • Shouval D, Lai CL, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside naïve, HBeAg negative chronic hepatitis B: results of phase III trail ETV-027. Hepatology 2004;40:S73
  • Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine refractory, HBeAg (+) chronic hepatitis B: results of a phase III study. ETV-026. Hepatology 2004;40:S664
  • Dienstag JL, Wei LJ, Xu D, et al. Entecavir is superior to lamivudine and adefovir in trials of HBeAg positive and negative hepatitis B infection: a cross-study analysis with published reports. J Hepatol 2005;42:S174
  • Gish R, Chang TT, de Man R, et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg (+) chronic hepatitis B patients (Study ETV-022). Hepatology 2005;42:S267A
  • Sherman M, Yurdaydin C, Sollano, et al. Entecavir for treatment of lamivudine-refractory, HBeAg positive chronic hepatitis B. Gastroenterology 2006;130:2039-49
  • Tenney DJ, Rose RF, Baldick CJ, et al. Two year assessment of entecavir resistance in lamivudine refractory hepatitis B virus patients reveals different clinical outcomes depending upon the resistance substitutions present. Antimicrob Agents Chemother 2007;51:902-11
  • Colonno R, Rose RE, Pokorowski K, et al. Four year assessment of ETV resistance in nucleoside naïve and lamivudine refractory patients. Presented at the 42nd Annual Meeting of EASL; 11 – 15 April 2007; Barcelona, Spain
  • Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg negative chronic hepatitis B. N Engl J Med 2006;354:1001-10
  • Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006;26:162-70
  • Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
  • Tenney DJ, Langley DR, Oliver AJ, et al. Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase. Hepatology 2004;40:245A
  • Lai CL, Gane E, Liaw YF, et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first year results from the international phase III GLOBE trial. Hepatology 2005;42:S748A
  • Lai Cl, Gane E, Hsu CW, et al. Two year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology 2006;44:222A
  • Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008;47:447-54
  • Marcellin P, Heathcote J, Gane E, et al. Tenofovir (TDF) showed superior antiviral efficacy to adefovir dipivoxil (ADV) at 48 weeks in two pivotal, randomized, double-blind studies for the treatment of HBeAg negative (–) and HBeAg positive (+) chronic hepatitis B (CHB): study 102 and study 103. Global Antivir J 2007;3:S67-8
  • Shiffman ML, Ng TM, Krastev Z, et al. A double-blind, placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once daily for treatment of chronic hepatitis B virus (HBV) infection [abstract 22]. Presented at the 55th Annual Meeting of the American Association for the Study of Liver Disease; October 29 – 2 November 2004; Boston, MA
  • Lee HS, Chung YH, Lee KS, et al. A 12 week clevudine therapy showed potent and durable antiviral activity in HBeAg positive chronic hepatitis B. Hepatology 2006;43:982-8
  • Lee CH, Chung KW, Lee JS, et al. Clevudine monotherapy showed rapid viral and biochemical response in chronic hepatitis B patients. Global Antivir J 2007;3:S31-2
  • Yoo BC, Kim JH, Chung YH, et al. Twenty-four week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
  • McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: who to treat. Am J Gastroenterol 2006;101:S7-12
  • Morgan M, Park W, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: an update. Minerva Gastroenterol Dietol 2007;53:25-41
  • Zizer E, Hasel C, Seufferlein T, et al. A 40-year-old female patient with seronegative autoimmune hepatitis following a newly acquired hepatitis B infection. Zeitschrift Gastroentero l2008;46:201-5
  • Naicker S, Fabian J, Naidoo S, et al. Infection and glomerulonephritis. Semin Immunopathol 2007;29:397-414
  • Safary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. J Gastroenterol Hepatol 2000;15:396-401
  • Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126-35
  • Altman A, Szyper-Kravitz M, Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association? Rheumatol Int 2008;28:609-12
  • Choffray A, Pinquier L, Bachelez H. Exacerbation of lupus panniculitis following anti-hepatitis-B vaccination. Dermatol 2007;215:152-4
  • Hsu TC, Tsay GJ, Chen TY, et al. Anti-PCNA autoantibodies preferentially recognize C-terminal of PCNA in patients with chronic hepatitis B virus infection. Clin Exp Immunol 2006;144:110-6
  • Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol 2005;142:377-80
  • Geier MR, Geier DA. A case-series of adverse event, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review. Clin Exp Rheumatol 2004;22:749-55
  • Schattner A. Consequence of conincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005;23:3876-86
  • Waisbren BA Sr. Acquired autoimmunity after viral vaccination is caused by molecular mimicry and antigen complimentarity in the presence of an immunologic adjuvant and specific HLA patterns. Med Hypoth 2008;70:346-8
  • Barzilai O, Ram M, Shoenfeld Y. Viral infection can induce the production of autoantibodies. Curr Opin Rheumatol 2007;19:636-43
  • Hann HWL, Lee JM, Bussard A, et al. Preneoplastic marker of hepatitis B virus associated hepatocellular carcinoma. Cancer Res 2004;64:7329-35
  • Tunca A, Erbayrak M, Aytac S, Turkay C. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol 2004;15:97-9
  • Kuloglu Z, Kansu A, Berberoglu M, et al. Effect of interferon treatment on glucose metabolism in children with chronic hepatitis B infection. Turk J Gastroenterol 2004;15:4-10
  • Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999;53:242-54
  • Malaguarnera M, Restuccia S, Motta M, et al. Interferon, cortisone, and antivirals in the treatment of chronic viral hepatitis: a review of 30 years of therapy. Pharmacotherapy 1997;17:998-1005
  • Riediger C, Berberat PO, Sauer P, et al. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 2007;22(Suppl 8):37-46
  • Lopez PM, Villanueva A, Llovet L. Systematic review: Evidence-based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-47
  • Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40
  • Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9
  • Lencioni R, Cioni D, Crocetti L, et al. Early stage hepatocellular carcinoma in patients with cirrhosis: long term results of percutaneous image guided radiofrequency ablation. Radiology 2005;234:961-7
  • Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004;127:S159-66
  • Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002;359:1734-9
  • Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresected hepatocellular carcinoma. Hepatology 2002;35:1164-71
  • Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474-84
  • Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/flurouracil (PIAF) combination chemotheraphy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8
  • Yeo W, Lam KC, Zee B, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-6
  • Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer 2007;97:582-8
  • Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25:3069-75
  • Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007;7:617-26
  • Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 2005;41:773-84
  • Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006;33:392-406
  • Benn J, Schneider RJ. Hepatitis B virus HBx protein activates ras-GTP complex formation and establishes a ras, raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994;91:10350-4
  • Tarn C, Lee S, Hu Y, et al. Hepatitis B virus X protein differentially activates RAS–RAF–MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001;276:34671-80
  • Lian Z, Liu J, Wu M, et al. Hepatitis B x antigen up-regulates vascular endothelium growth factor receptor 3 in hepatocarcinogenesis. Hepatology 2007;45:1390-9
  • Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005;102:3389-94
  • Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
  • Geier A, Gartung C, Dietrich CG. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:1721-2
  • Hann HW. Active antiviral therapy for chronic hepatitis B and hepatocellular carcinoma. Minerva Gastroenterol Dietol 2008;54:19-30
  • Lampertico P, Vigano M, Iavarone M, et al. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir–lamivudine combination therapy for 3 years [abstract]. Hepatology 2006;44:S556A
  • Rapti I, Dimou E, Mitsoula P, et al. Adding on versus switching to adefovir therapy in lamivudine resistant HBeAg negative chronic hepatitis B. Hepatology 2007;45:307-13
  • Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12
  • Jacquard AC, Nassal N, Pichoud C, et al. Effect of a combination of clevudine and emtricitabine and adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infections. Antimicrob Agents Chemother 2004;48:2683-92
  • Menne S, Cote PJ, Korba BE, et al. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 2005;49:2720-8
  • Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45
  • Anderson AL, Banks KE, Pontoglio M, et al. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice. J Virol 2005;79:11045-52
  • Iyer RP, Roland A, Jin Y, et al. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob Agents Chemother 2004;48:2318-20
  • Larkin J, Clayton MM, Sun B, et al. Hepatitis B virus transgenic SCID mouse model of chronic liver disease. Nat Med 1999;5:907-12
  • Feitelson MA, Clayton MM, Sun BS, Schinazi RF. Development of a novel mouse model to evaluate drug candidates against hepatitis B virus. Antiviral Chem Chemother 2007;18:213-23
  • Kamkolkar M, Clayton MM, Zhang SM, et al. Evaluation of therapies for hepatitis B virus in the HBV transgenic SCID mouse model. In: Schinazi RF, Rice C, Sommadossi P, editors, Frontiers in viral hepatitis. St. Louis, MO: Elsevier; 2002. p. 211-22
  • Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997;41:1715-20
  • Feitelson MA. Molecular and genetic determinants of primary liver malignancy. In: Khatri VP, Schneider PD, editors, Surgical clinics of North America. Liver surgery: modern concepts and techniques. Volume 84. Philadelphia: WB Saunders Co; 2004. p. 339-54
  • Feitelson MA. Hepatitis B virus in hepatocarcinogenesis. J Cell Physiol 1999;181:188-202
  • Feitelson MA, Reis H, Liu J, et al. Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Volume 10. In: Zhao R, editor, Frontiers in bioscience. Viral infection and cell cycle control. Albertson, NY: Frontiers in Bioscience; 2005. p. 1558-72

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.